Adverse Drug Effects

Report Urges Closer Look at Cardiotoxicity of Breast Cancer Drug Trastuzumab (Herceptin)

Published in Medical Letter on the CDC and FDA, August 6th, 2000

Although trastuzumab (Herceptin) has been lauded as being beneficial in the treatment of breast cancer, its use is associated with a high incidence of cardiac toxicity and raises important questions about mechanisms of action, appropriate patient monitoring, and risk/benefit ratio, according to a report published in the current issue of Circulation.

Written by a cardiologist at the University of Pittsburgh Medical Center, the report further states that the extension of trastuzumab use to patients with less invasive forms of breast cancer seems imprudent in view of untoward cardiac effects and should be reconsidered until additional information is available. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-08-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry